Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KALA - Kala Bio Inc.


Previous close
5.89
0   0%

Share volume: 1,560
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$5.89
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
22%
Profitability 18%
Dept financing 21%
Liquidity 73%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
-2.66%
1 Month
-9.58%
3 Months
-9.30%
6 Months
-18.58%
1 Year
-56.67%
2 Year
-58.52%
Key data
Stock price
$5.89
P/E Ratio 
-3.12
DAY RANGE
N/A - N/A
EPS 
-$4.55
52 WEEK RANGE
$4.21 - $13.19
52 WEEK CHANGE
-$0.56
MARKET CAP 
26.955 M
YIELD 
N/A
SHARES OUTSTANDING 
4.608 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
0.41
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$6,042
AVERAGE 30 VOLUME 
$14,981
Company detail
CEO: Mark Iwicki
Region: US
Website: http://kalarx.com/
Employees: 111
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.

Recent news